GEMALTO
9.10.2018 07:02:11 CEST | Business Wire | Press release
Gemalto, the world leader in digital security, today released the latest findings of the Breach Level Index , a global database of public data breaches, revealing 945 data breaches led to 4.5 billion data records being compromised worldwide in the first half of 2018. Compared to the same period in 2017, the number of lost, stolen or compromised records increased by a staggering 133 percent, though the total number of breaches slightly decreased over the same period, signaling an increase in the severity of each incident.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181008005322/en/
A total of six social media breaches, including the Cambridge Analytica-Facebook incident, accounted for over 56 percent of total records compromised. Of the 945 data breaches, 189 (20 percent of all breaches) had an unknown or unaccounted number of compromised data records.
The Breach Level Index is a global database that tracks data breaches and measures their severity based on multiple dimensions, including the number of records compromised, the type of data, the source of the breach, how the data was used, and whether or not the data was encrypted. By assigning a severity score to each breach, the Breach Level Index provides a comparative list of breaches, distinguishing data breaches that are not serious versus those that are truly impactful.
According to the Breach Level Index, almost 15 billion data records have been exposed since 2013, when the index began benchmarking publicly disclosed data breaches. During the first six months of 2018, more than 25 million records were compromised or exposed every day, or 291 records every second, including medical, credit card and/or financial data or personally identifiable information. This is particularly concerning, since only one percent of the stolen, lost or compromised data records were protected by encryption to render the information useless, a percent-and-a-half drop compared to the first six months of 2017.
"Obviously, this year social media has been the top industry and threat vector for the compromise of personal data, a trend we can expect to continue with more and more sectors leveraging these platforms to reach key audiences, especially political teams gearing up for major elections," said Jason Hart, vice president and chief technology officer for data protection at Gemalto. "We also expect to see more data breaches reported by European Union countries bound by the new General Data Protection Regulation and in Australia with the new Notifiable Data Breaches law. We should be careful not to misconstrue this as an increase in overall incidents in these areas but rather as a more accurate reflection of what is actually going on."
Primary Sources of Data Breaches
Malicious outsiders caused
the largest percentage of data breaches (56 percent), a slight decrease
of almost seven percent over the second half of 2017 and accounted for
over 80 percent of all stolen, compromised or lost records. Accidental
loss accounted for over 879 million (9 percent) of the records lost this
half, the second most popular cause of data breaches representing over
one third of incidents. The number of records and incidents involved in
malicious insider attacks fell by 50 percent this half compared to the
same time period in 2017.
Leading Types of Data Breaches
Identity theft continues to
be the leading type of data breach, as it has been since Gemalto first
started tracking in 2013. While the number of identity theft breaches
increased by 13 percent over the second half of 2017 to just over 64
percent, the number of records stolen through these incidents increased
by 539 percent, representing over 87 percent of all records stolen.
Financial access incidents show a disturbing trend in the escalation of severity. Though overall incident numbers are on the decline H1 2017 vs. H1 2018 (171 for H1 2017 and 123 for H1 2018), the number of records breached increased H1 2017 vs. H1 2018 (2.7 million and 359million) respectively.
Industries Most Affected by Data Breaches
Most sectors saw
an increase in the number of incidents compared to the previous half –
the exceptions were government, professional services, retail and
technology, though both government and retail saw an increase in the
number of records breached through fewer events.
Healthcare continues to lead in number of incidents (27 percent). The largest such incident, 211 LA County, exposed 3.5 million records through accidental loss.
Social media ranks top for number of records breached (56 percent) due to the high-profile customer data compromises at Facebook and Twitter, involving 2.2 billion and 336 million respectively.
Geographic Distribution of Data Breaches
North America still
makes up the majority of all breaches and the number of compromised
records, 59 and 72 percent respectively. The United States is still by
far and away the most popular target for attacks, representing more than
57 percent of global breaches and accounting for 72 percent of all
records stolen, though overall incidents are down 17 percent over the
prior half.
With the implementation of the Notifiable Data Breaches law, the number of incidents in Australia increased dramatically from 18 to 308 as could be expected.
Europe saw 36 percent fewer incidents but a 28 percent increase in the number of records breached indicating growing severity of attacks. The United Kingdom remains the most breached country in the region. With the General Data Protection Regulation in full effect for the second half of 2018, the number of reported incidents could begin to rise.
Related Resources:
- For a full summary of data breach incidents by industry, source, type and geographic region, download the First Half 2017 Breach Level Index Report
- Download the infographic here
- Visit the BLI website here
About Gemalto
Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security , with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.
From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.
Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.
Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.
For more information visit www.gemalto.com , or follow @gemalto on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181008005322/en/
Contact:
Gemalto media contacts: Tauri Cox North America +1 512 257 3916 tauri.cox@gemalto.com or Sophie Dombres Europe Middle East & Africa +33 4 42 36 57 38 sophie.dombres@gemalto.com or Piyush Prakash Asia Pacific +91 11 6623 1200 piyush.prakash@gemalto.com or Enriqueta Sedano Latin America +52 5521221422 enriqueta.sedano@gemalto.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
